Catalent Appoints Two Industry Leaders to Support Growth in its Clinical Supply Service European Network
Catalent Pharma Solutions has announced the appointment of two General Managers to oversee key Clinical Supply Services facilities in its European network.
Mr Alan Robinson has been appointed to oversee operations at the company’s Bolton and Deeside, UK facilities. In this new role, Mr Robinson will drive uptake in the Clinical Supply Services provided by both sites, and leverage their complementary expertise to provide innovative solutions to customers.
“The Bolton and Deeside sites operate very much like sister facilities due to their close proximity and mirrored and complementary capabilities. This appointment allows Mr Robinson to leverage the breadth of services and technical expertise across both sites to the benefit of our customers,” commented Stuart Cryer, Vice President, Operations, Development and Clinical Services, Europe and Rest of World for Catalent.
A 30-year industry veteran, Mr Robinson’s areas of expertise include operations management, strategic planning, and the application of continuous performance improvement methodologies, including Six Sigma and Lean Manufacturing. He was formerly Senior Director and Site Head for Aptuit.
In a second announcement, Mr Roel de Nobel has been appointed General Manager of Catalent’s Schorndorf, Germany Clinical Supply Services facility, and will focus on driving operational excellence to support clients’ clinical trial needs. Mr de Nobel brings more than 20 years of experience in logistics, supply chain and financial management to Catalent, most recently as the Global Director, Logistics Management for Carl ZEISS AG.
“Mr de Nobel has an impressive operations and supply chain track record in highly complex businesses, and we are very pleased to welcome him to Catalent to lead our Schorndorf operations,” added Stuart Cryer.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance